
    
      This is a phase II, single-arm study of combination therapy of avelumab, haNK, and N-803 in
      patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor
      therapy as assessed by ORR. Patients must have progressed on or within six months of
      completing treatment with either avelumab or pembrolizumab. Patients will received treatment
      for a maximum of two years, with avelumab and haNK administered every two weeks, and N-803
      administered every three weeks. Radiologic evaluation will occur every eight weeks during the
      first year of treatment, and every twelve weeks during the second year of treatment.
    
  